Tokyo, Japan and also Cambridge, UK, 8 March 2023— Sosei Team Firm (” the Firm”; TSE: 4565), the globe leader in G protein-coupled receptor (GPCR) concentrated structure-based medicine style (SBDD) and also advancement, delights in to introduce it has actually gotten authorization from the Tokyo Stock Market, Inc. (” TSE”) to alter the marketplace on which the Firm’s shares are detailed from the Development Market section to the Prime Market section, reliable March 15, 2023.
We are deeply thankful to our investors and also stakeholders for their ongoing assistance over several years. Sosei Heptares is participated in medicine exploration and also advancement that calls for a long-term financial investment perspective, and also for that reason this long-term assistance has actually been important in permitting us to develop a strong business, able to transfer to the Prime Market.
We will certainly remain to concentrate on our objective to turn into one of Japan’s international biopharmaceutical champs seeking our objective to create life-altering medications making use of world-leading scientific research and also modern technology and also aim to additional raising the Firm’s company worth over the long-term.
For additional information concerning the modification of our market section providing to the TSE Prime Market, please see the Japan Exchange Team’s web site (https://www.jpx.co.jp/english/).
– FINISHES–
Regarding Sosei Heptares
We are a worldwide biopharmaceutical team concentrated on the exploration and also very early advancement of brand-new medications stemming from our exclusive GPCR-targeted celebrity ® modern technology and also structure-based medicine style system capacities. We are progressing a wide and also deep pipe of unique medications throughout numerous healing locations, consisting of neurology, immunology, gastroenterology, and also inflammatory conditions.
We have actually developed collaborations with several of the globe’s leading pharmaceutical business and also numerous arising modern technology business, consisting of AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Takeda and also Verily. Sosei Heptares is headquartered in Tokyo, Japan with company and also R&D centers in Cambridge, UK.
” Sosei Heptares” is the company brand name and also hallmark of Sosei Team Firm, which is detailed on the Tokyo Stock market (ticker: 4565). Sosei, Heptares, the logo design and also celebrity ® are hallmarks of Sosei Team business.
For additional information, please go to https://soseiheptares.com/
LinkedIn: @soseiheptaresco|Twitter: @soseiheptaresco|YouTube: @soseiheptaresco
Enquiries:
Sosei Heptares– Media and also Capitalist Relations
Hironoshin Nomura, Principal Financial Policeman
Shinichiro Nishishita, VP Capitalist Relations, Head of Regulatory Disclosures
Candelle Chong, SVP Capitalist Relations and also Corporate Method
Japan: +81 (0 )3 5210 3399| UK: +44 (0 )1223 949390| [email protected]
MEDiSTRAVA Consulting (for International Media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0 )203 928 6900| [email protected]
Positive s tatements
This news release includes progressive declarations, consisting of declarations concerning the exploration, advancement, and also commercialization of items. Numerous threats might trigger Sosei Team Firm’s real outcomes to vary materially from those revealed or suggested by the progressive declarations, consisting of: negative lead to medical advancement programs; failing to get license security for developments; business restrictions enforced by licenses possessed or regulated by 3rd parties; dependancy upon calculated partnership companions to create and also market product or services; problems or hold-ups in getting regulative authorizations to market product or services arising from advancement initiatives; the demand for significant financing to perform r & d and also to increase commercialization tasks; and also item campaigns by rivals. As an outcome of these elements, possible capitalists are warned not to depend on any kind of progressive declarations. We disclaim any kind of purpose or commitment to upgrade or change any kind of progressive declarations, whether as an outcome of brand-new details, future occasions or otherwise.
